With regard to the HER2-negative cancers, our
observation of an apparent loss of heterozygosity
(LOH) for the two variants in a significant proportion of
cases (54% and 57%) seems to contrast with previous
work. However, LOH in chromosome 17 is among the
most common genetic alterations in breast cancer
[40,41]. In particular, LOH was observed in two
microsatellites polymorphisms located on 17q close to
the HER2 gene in over 40% of cases (among 49 and 87
informative samples)